You are here
Articles
Posted on Wednesday, May 6, 2015 - 4:16pm
A small retrospective study of heavily pretreated patients with chronic myeloid leukemia (CML) found bosutinib to be a good option in the fourth-line setting.
Posted on Saturday, April 11, 2015 - 1:58pm
News | April 06, 2015 | Chronic Myeloid Leukemia, Hematologic Malignancies, Leukemia & Lymphoma
By Ian Ingram
A small retrospective study of heavily pretreated patients with chronic myeloid leukemia (CML) found...
Posted on Saturday, April 11, 2015 - 1:52pm
A Burchert1, S Saussele2, E Eigendorff3, M C Müller2, K Sohlbach1, S Inselmann1, C Schütz1, S K Metzelder1, J Ziermann3, P Kostrewa1, J Hoffmann1, R Hehlmann2, A Neubauer1 and A Hochhaus3
Abstract
A...
Posted on Wednesday, March 25, 2015 - 4:03pm
C M Lucas1, R J Harris1, A K Holcroft1, L J Scott1, N Carmell1, E McDonald1, F Polydoros2 and R E Clark1
1Section of Haematology, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool...
Posted on Wednesday, March 25, 2015 - 2:52pm
News | March 17, 2015 | Chronic Myeloid Leukemia, Hematologic Malignancies, Leukemia & Lymphoma
By Cancer Network Staff
A single-arm, open-label trial in Australia found that selective early switching from imatinib...
Posted on Tuesday, March 17, 2015 - 12:02pm
Simona Soverini1, Andreas Hochhaus2, Franck E. Nicolini3, Franz Gruber4, Thoralf Lange5, Giuseppe Saglio6, Fabrizio Pane7,8, Martin C. Müller9, Thomas Ernst2, Gianantonio Rosti1, Kimmo Porkka10, Michele Baccarani1,...
Posted on Thursday, January 22, 2015 - 2:12pm
There has been substantial interest in intermittent or other alternative scheduling of tyrosine kinase inhibitors in treatment for CML. The success of the drugs has been remarkable, but because of that success and the...
Posted on Thursday, January 22, 2015 - 2:10pm
January 13, 2015 | Chronic Myeloid Leukemia, ASH 2014, Hematologic Malignancies, Leukemia & Lymphoma
By Dave Levitan
Despite the early termination of a phase III trial due to safety concerns, an analysis suggests...
Posted on Friday, January 9, 2015 - 6:03pm
The tyrosine kinase inhibitor (TKI) imatinib has revolutionized the management of chronic myeloid leukaemia (CML). However, around 25% of patients fail to sustain an adequate response. We sought to identify gene-...
Posted on Wednesday, January 7, 2015 - 6:13pm
L Schafranek E Nievergall, J A Powell D K Hiwase T Leclercq T P Hughes and D L White
Kinase inhibitors block proliferative signals in BCR-ABL1+ leukemic cells, but their capacity to induce apoptosis is poorly understood...
Posted on Monday, January 5, 2015 - 12:21pm
November 28, 2014
Hematologists from Goethe University Frankfurt, working with a Russian pharmaceutical company, have developed a new active substance that effectively combats the most aggressive forms of Philadelphia...
Posted on Monday, January 5, 2015 - 12:11pm
Practice Update Editorial Team, 2014 Dec 07
December 7, 2014 – San Francisco, California – A high prevalence of platelet dysfunction has been demonstrated in patients with chronic myeloid leukemia (CML) receiving all...
Posted on Monday, December 15, 2014 - 2:47pm
Professor Steve O’Brien, Newcastle University, UK
Posted on Tuesday, December 9, 2014 - 12:34pm
A A Mian1, A Rafiei1, I Haberbosch1, A Zeifman2,3, I Titov2,3, V Stroylov2,3, A Metodieva1, O Stroganov2,3, F Novikov2,3, B Brill4, G Chilov2,3, D Hoelzer1, O G Ottmann1 and M Ruthardt1
1Department of Hematology, Goethe...
Posted on Tuesday, December 9, 2014 - 12:14pm
Tun Kiat Ko1, Charles T.H. Chuah1,2, John W.J. Huang1 , King-Pan Ng1 and S. Tiong Ong
- ‹ previous
- 10 of 33
- next ›